Future looks bright21 Aug 2021 15:54
Sanofi announced on June 19, 2018 that it has completed its $4.8-billion acquisition of Ablynx, a biopharmaceutical company based in Ghent, Belgium, that develops proprietary therapeutic proteins based on single-domain antibody fragments.
Now on a interview with Paul Hill on vox earlier this year, Paul asked AS about being taken over and AS started to talk about Ablynx but Paul interrupted.
The Sanofi deal was 3 years ago and as Myles said in his notes Ablynx did not have a diagnostic business attached.
With Avacta having 3 large bites at billions in Precision
TMac and the Affidx portfolio plus all the licence agreements with major Pharma companies.I think if Avacta receives a takeover approach it will smash the Ablynx price.
Myles conclusion on his Investment notes.
As a reminder, a competing antibody mimetic technology to Affimer Therapeutics was acquired three years ago for $4.8 billion cash. Although 5-6 years ahead in terms of clinical development, the antibody mimetic platform in question – Nanobodies – was not being used in Diagnostic
Be patient everyone good luck.